



BETTER SLEEP, BETTER HEALTH
and a BETTER LIFE

29 June 2017

ASX RELEASE

Cleansing Notice – Placement

Oventus Medical Limited (ASX: OVN) (**Oventus**) today issued 17,916,660 fully paid ordinary shares to institutional and sophisticated investors by way of a first tranche placement, at an issue price of \$0.36 per share as outlined in Oventus' announcement of 22 June 2017.

Oventus has issued the shares without disclosure to investors under section 708A(5) *Corporations Act 2001* (Cth) (**Corporations Act**).

Details of the securities issued

Class of securities:	Ordinary shares
ASX Code of the securities:	OVN
Date of the issue of the securities:	Thursday 29 June 2017
Total number of securities issued or expected to be issued:	17,916,660

As required by section 708A(6) of the Corporations Act, Oventus advises:

- (a) the shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Oventus has complied with:
 - (i) the provisions of chapter 2M of the Corporations Act as they apply to Oventus; and
 - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act).

An Appendix 3B reflecting the revised capital structure following the issue of the shares under the placement has been separately announced.

For and on behalf of the board of Oventus.

Mel Bridges
Chairman
Oventus Medical Limited

-ENDS-

For more information please contact:

Dr Mel Bridges, Chairman: M: 0413 051 600 (+61 41 3051 600)

Kyahn Williamson, WE Buchan: P: 03 8866 1214 or kwilliamson@buchanwe.com.au

About Oventus

Oventus is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

A clinical study completed earlier this year showed the company's first generation product the O2Vent MonoTM is successful in treating OSA and that snoring was either eliminated or significantly reduced in 100 per cent of patients. The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep. It also improves oxygen levels for patients.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP². Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.³

¹ *Deloitte Access Economics. Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² *Beecroft, et al. Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003*

³ *Sutherland et al. Oral appliance treatment for obstructive sleep apnea: An updated Journal of Clinical Sleep Medicine. February 2014.*